/

Empresas

Gr

No verificado

Grünenthal Group

Sobre qué escribimos

EconomíaFarmacéuticaFitnessSaludSanidad

14 Comunicados de prensa

Ver todos los comunicados de prensa

16/07/2026

Medio Ambiente/Ecología

Agricultura

Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich

Fuente

Grünenthal Group

Editor

1.00

0

08/07/2026

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy

Fuente

Grünenthal Group

Editor

1.00

0

29/06/2026

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist

Fuente

Grünenthal Group

Editor

1.00

0

05/03/2026

Salud

Fitness

Empresas

Industria

Medicina - Varios

Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm

Fuente

Grünenthal Group

Editor

1.00

0

02/03/2026

Salud

Fitness

Empresas

Industria

Medicina - Varios

Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands

Fuente

Grünenthal Group

Editor

1.00

0

02/06/2025

Farmacéutica

Sanidad

Economía

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia

Fuente

Grünenthal Group

Editor

1.00

0

20/05/2025

Farmacéutica

Sanidad

Economía

Gestión empresarial

Administración de Empresas

Maren Thurow starts as new Head Global Communications at Grünenthal

Fuente

Grünenthal Group

Editor

1.00

0

24/02/2025

Farmacéutica

Banca

Sanidad

Economía

Patentes, marcas y derechos de autor

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

Fuente

Grünenthal Group

Editor

1.00

0

09/01/2025

Farmacéutica

Sanidad

Economía

Gestión empresarial

Administración de Empresas

Biología

Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer

Fuente

Grünenthal Group

Editor

1.00

0

07/11/2024

Farmacéutica

Sanidad

Economía

Start-up

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Fuente

Grünenthal Group

Editor

1.00

0

Seguidores

0

Compatibilidad

0